

PATENT APPLICATION

RECOMBINANT VANADIUM HALOPEROXIDASES  
AND THEIR USES

Inventors:

Valerie Vreeland  
Kwan L. Ng

Assignee:

Regents of the University of California

TOWNSEND and TOWNSEND and CREW LLP  
Two Embarcadero Center, 8th Floor  
San Francisco, California 94111-3834  
(415) 576-0200

## RECOMBINANT VANADIUM HALOPEROXIDASES AND THEIR USES

### FIELD OF THE INVENTION

The present invention relates to cloning and recombinant expression of proteins. In particular, it relates to expression of vanadium bromoperoxidase polypeptides.

### BACKGROUND OF THE INVENTION

Vanadium haloperoxidase enzymes are useful in industrial catalysis in a variety of contexts (Sheffield, *et al.*, *Biotechnology Techniques*, 8:579-582 (1994)). For instance, they catalyze a variety of halogenation, oxidation and epoxidation reactions (Itoh, *et al.*, *Eur. J. Biochem.*, 172:477 (1988); Itoh, *et al.* *Biochimica et Biophysica Acta.*, 1994 (1993); Itoh, *et al.*, *Appl. Microbiol. & Biotechnol.*, 43:394-401 (1995)). Although a halide ion is a required cofactor for enzyme activity, products may not be halogenated. Numerous uses in synthetic organic chemistry include reactions with diverse substrates such as aliphatic and aromatic hydrocarbons, phenols,  $\beta$ -diketones and nitrogen- and sulfur-containing heterocycles (Itoh, *et al.*, *Eur. J. Biochem.* 172:477 (1988); Neidleman *et al.*, *Biohalogenation: Principles, Basic Roles and Applications*, Ellis Horwood, John Wiley & Sons, New York (1986)). Bromoperoxidases can also be used in place of synthetic organic chemistry reactions to make activated intermediates or products such as pesticides. In addition, these enzymes have an advantage over chemical synthesis in producing stereospecific products (Itoh, *et al.*, *Eur. J. Biochem.*, 172:477 (1988)). Moreover, haloperoxidases have unusual stability (both temporal and thermal) and are active in solvents including methanol, ethanol and acetone.

Recent medical applications of bromoperoxidase have been described. Lovqvist, *et al.*, *Nuclear Medicine and Biology*, 22:125-131 (1995) described the enzymatic bromination of a monoclonal antibody with BR-radionuclide for imaging of

antibody localization by PET scanning. There is current interest in enzymatic production of antibiotics including fosfomycin and pyrrolnitrin (Itoh, *et al. Biochimica et Biophysica Acta*. 1994 (1993); Itoh, *et al., Appl. Microbiol. & Biotechnol.* 43:394-401 (1995)) and 7-chlorotetracycline (van Pée, K.H., *J. Bacteriol.*, 170:5890-5894 (1988)) via

5 haloperoxidase-catalyzed reactions in bacteria.

Known haloperoxidases include bromoperoxidases from brown and red algae including *Fucus* and *Ascophyllum* (Butler, *et al., Chem. Rev.*, 93:1937-1994 (1993)), iodoperoxidase from green algae (Mehrtens, G., *Polar Biol.* 14:351-354 (1994)), and chloroperoxidase from the fungus *Curvularia inaequalis* (Van Schijndel, *et al., Eur. J. Biochem.*, 225:151-157 (1994)). A vanadate requirement for algal haloperoxidase was first described by Vilter (Vilter, H., *Biological Systems*, 31, *Vanadium and its role in life*, Sigel, *et al.* (Eds.), Marcel Dekker, New York, N.Y., pp. 325-362 (1995)).

10

The specific bromoperoxidase activity of the native *Fucus* enzyme is several fold higher (Butler, *et al.*) than the other algal enzymes for which at least partial sequences have been reported, *Ascophyllum* (Vilter 1995) and *Corallina* (Shimonishi, *et al. FEBS Letters*, 428, 105-110 (1998)), and higher specific activity than the *Curvularia* fungal chloroperoxidase (van Schijndel *et al. BBA* 1161:249-256 (1993)).

15

Extracted and partially purified bromoperoxidase from the red alga *Corallina officinalis* is commercially available from Sigma Chemical Company. Sigma

20 has also investigated immobilization of enzyme on agarose beads (Sheffield, *et al., Phytochemistry*, 38:1103-1107 (1995)) and on cellulose acetate membrane (Sheffield, *et al., Biotechnology Techniques*, 8:579-582 (1994)) for repetitive catalysis of bromination reactions in flow-through reactors in enzyme-driven preparative organic chemistry. Many industrial uses for stable soybean peroxidase are envisioned by A. Pokora of Enzymol

25 International, Inc. as described by Wick (Wick, C.B., *Genetic Engineering News*, 16(3):1, 18-19). Recombinant enzyme biotechnology is of current industrial interest because enzymes are safe, low-polluting alternatives to chemicals in many applications, and can be modified by protein engineering to fit the requirements of specific applications (Kelly, E.B. *Genetic Engineering News*, 16(5):1, 30, 32 (1996) Lovqvist, *et al., Nuclear*

30 *Medicine and Biology*, 22:125-131 (1995)). Peroxidases can also be incorporated into moldable plastics (Service, R.F., *Science* 272:196-197 (1996)).

Multiple representatives of other classes of peroxidases have been produced in recombinant form. A heme peroxidase, manganese peroxidase from the fungus *Phanerochaete chrysosporidium*, was expressed in recombinant form and refolded for activity (Whitwam, R.E., *Biochem. Biophys. Research. Communications*, 216:1013-1017 (1995)). Recombinant horseradish peroxidase isozyme C (a heme peroxidase) for use in chemiluminescent labeling in molecular biology and biotechnology applications has been described (EP 0299682, WO 89/03424 ). Recombinant non-heme haloperoxidases have been prepared from the bacteria, *Pseudomonas pyrrocinia* (Wolfframm, *et al.*, *Gene* 130:131-135 (1993)) and two related *Streptomyces aureofaciens* enzymes (van Pée, K.H., *J. Bacteriol.*, 170:5890-5894 (1988); Pfeifer, *et al.*, *J. Gen. Microbiol.* 138:1123-1131 (1992)).

Despite the interest in vanadium haloperoxidases, there are relatively few reports in the literature of the cloning and recombinant expression of a vanadium haloperoxidases. Shimonshi *et al.* *FEBS Lett.* 428:105-110 (1998) described cloning of the enzyme from *Corallina pilulifera*. Cloning of the *Curvularia* gene is described by Hemrika, *et al.* *PNAS* 94,2145-2149 (1997) and 95/27046. A partial sequence of the *Ascomyllum* gene is described in Vitel (1995). There is a need in the art for efficient means for producing vanadium haloperoxidases using techniques such as recombinant expression. The present invention addresses these and other needs.

### SUMMARY OF THE INVENTION

The present invention provides isolated nucleic acids comprising a polynucleotide sequence encoding a vanadium bromoperoxidase polypeptide comprising an amino acid sequence having at least 90% amino acid sequence identity to an amino acid sequence from residue 441 to residue 676 as set forth in SEQ ID NO:2. The polypeptides of the invention catalyze the oxidation of o-dianisidine (ODA) when complexed with a vanadium ion. The polynucleotide sequence usually has at least 60% sequence identity to a sequence as set forth in SEQ ID NO:1.

The polypeptides of the invention can be of various sizes. Typically, the polypeptides have molecular weight of about 73.4 kD, usually the polypeptide has a molecular weight of about 58 kD, or sometimes at least about 40 kD.

The invention also provides expression cassettes comprising a heterologous promoter operably linked to the polynucleotide sequences of the invention. The promoter can be active in a prokaryotic cell, such as a bacterium. Also provided are cells the expression cassette of the invention.

The invention further provides methods for enzymatically halogenating or oxidizing a compound using the polypeptides of the invention.

### Definitions

A "vanadium bromoperoxidase polypeptide" of the invention is an isolated protein capable of catalyzing the oxidation of o-dianisidine (ODA) when complexed with a vanadium ion. Vanadium bromoperoxidases of the invention can also be identified by the presence of a conserved C terminal region located from residue 441 to residue 676 in SEQ ID NO:2. Polypeptides of the invention typically have a sequence at least about 90% identical (as determined below), usually at least about 95% identical to the sequence from residue 441 to residue 676 in SEQ ID NO:2. One of skill will recognize that the sequence of the polypeptide can be altered without substantially altering activity of the polypeptide (e.g., by conservative substitutions). In addition, as explained below, less conservative modifications (e.g., substitutions, additions, and deletions) can be made to facilitate proper refolding, purification, and the like, as desired.

Full length vanadium bromoperoxidase polypeptides of the invention typically have a mass of about 73.4 kD, and have a sequence as shown in SEQ ID NO:2. One of skill will recognize that shorter vanadium bromoperoxidase polypeptides can also be used. For instance, the polypeptides can consist essentially of the C terminal region described above. The polypeptides may thus comprise from about 300 amino acids to about 680 amino acids, or from about 500 to about 600 amino acids. Exemplary polypeptide having a mass of about 60 kD and 40 kD are described in detail below.

A "polynucleotide sequence encoding a vanadium bromoperoxidase polypeptide" of the invention is a polynucleotide which encodes a vanadium peroxidase polypeptide as described above. An exemplary sequence is provided in SEQ ID NO:1. One of skill can readily make nucleic acid molecules encoding polypeptides within the scope of the invention. Thus, the nucleic acids of the invention can be altered by substitutions, deletions, and additions, as desired. Polynucleotide sequences of the

invention will typically be at least about 60%, usually at least about 70%, more usually at least about 80%, and often at least about 90% or 95% identical to SEQ ID NO:1.

Polynucleotides of the invention can also be identified by their ability to hybridize under defined conditions to a nucleic acid having SEQ ID NO:1. Means for determining this are described in detail below.

A polynucleotide sequence is "heterologous to" an organism or a second polynucleotide sequence if it originates from a foreign species, or, if from the same species, is modified from its original form. For example, a promoter operably linked to a heterologous coding sequence refers to a coding sequence from a species different from that from which the promoter was derived, or, if from the same species, a coding sequence which is different from any naturally occurring allelic variants.

A polynucleotide "exogenous to" an individual organism or cell is a polynucleotide which is introduced into the organism or cell using genetic engineering techniques.

The phrase "nucleic acid sequence" refers to a single or double-stranded polymer of deoxyribonucleotide or ribonucleotide bases read from the 5' to the 3' end. It includes chromosomal DNA, self-replicating plasmids, infectious polymers of DNA or RNA and DNA or RNA that performs a primarily structural role..

A "promoter" is defined as an array of nucleic acid control sequences that direct transcription of an operably linked nucleic acid. Promoters include necessary nucleic acid sequences near the start site of transcription, such as, in the case of a polymerase II type promoter, a TATA element. A promoter also optionally includes distal enhancer or repressor elements, which can be located as much as several thousand base pairs from the start site of transcription. A "constitutive" promoter is a promoter that is active under most environmental and developmental conditions. An "inducible" promoter is a promoter that is active under environmental or developmental regulation. The term "operably linked" refers to a functional linkage between a nucleic acid expression control sequence (such as a promoter, or array of transcription factor binding sites) and a second nucleic acid sequence, wherein the expression control sequence directs transcription of the nucleic acid corresponding to the second sequence.

In the case where the inserted polynucleotide sequence is transcribed and translated to produce a functional polypeptide, one of skill will recognize that because of

codon degeneracy a number of polynucleotide sequences will encode the same polypeptide. In addition, the term specifically includes those sequences substantially identical (determined as described below) with polynucleotide sequences disclosed here.

5 The terms "identical" or percent "identity," in the context of two or more nucleic acids or polypeptide sequences, refer to two or more sequences or subsequences that are the same or have a specified percentage of amino acid residues or nucleotides that are the same, when compared and aligned for maximum correspondence over a comparison window, as measured using one of the following sequence comparison algorithms or by manual alignment and visual inspection. When percentage of sequence identity is used in reference to proteins or peptides, it is recognized that residue positions that are not identical often differ by conservative amino acid substitutions, where amino acids residues are substituted for other amino acid residues with similar chemical properties (e.g., charge or hydrophobicity) and therefore do not change the functional properties of the molecule. Where sequences differ in conservative substitutions, the percent sequence identity may be adjusted upwards to correct for the conservative nature of the substitution. Means for making this adjustment are well known to those of skill in the art. Typically this involves scoring a conservative substitution as a partial rather than a full mismatch, thereby increasing the percentage sequence identity. Thus, for example, where an identical amino acid is given a score of 1 and a non-conservative substitution is given a score of zero, a conservative substitution is given a score between zero and 1. The scoring of conservative substitutions is calculated according to, e.g., the algorithm of Meyers & Miller, *Computer Applic. Biol. Sci.* 4:11-17 (1988) e.g., as implemented in the program PC/GENE (Intelligenetics, Mountain View, California, USA)..

25 The phrase "substantially identical," in the context of two nucleic acids or polypeptides, refers to sequences or subsequences that have at least 60%, preferably 80%, most preferably 90, 95% nucleotide or amino acid residue identity when aligned for maximum correspondence over a comparison window as measured using one of the following sequence comparison algorithms or by manual alignment and visual inspection. This definition also refers to the complement of a test sequence, which has substantial sequence or subsequence complementarity when the test sequence has substantial identity to a reference sequence.

For sequence comparison, typically one sequence acts as a reference sequence, to which test sequences are compared. When using a sequence comparison algorithm, test and reference sequences are entered into a computer, subsequence coordinates are designated, if necessary, and sequence algorithm program parameters are designated. Default program parameters can be used, or alternative parameters can be designated. The sequence comparison algorithm then calculates the percent sequence identities for the test sequences relative to the reference sequence, based on the program parameters.

A "comparison window", as used herein, includes reference to a segment of any one of the number of contiguous positions selected from the group consisting of from 20 to 600, usually about 50 to about 200, more usually about 100 to about 150 in which a sequence may be compared to a reference sequence of the same number of contiguous positions after the two sequences are optimally aligned. Methods of alignment of sequences for comparison are well-known in the art. Optimal alignment of sequences for comparison can be conducted, e.g., by the local homology algorithm of Smith & Waterman, *Adv. Appl. Math.* 2:482 (1981), by the homology alignment algorithm of Needleman & Wunsch, *J. Mol. Biol.* 48:443 (1970), by the search for similarity method of Pearson & Lipman, *Proc. Nat'l. Acad. Sci. USA* 85:2444 (1988), by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Dr., Madison, WI), or by manual alignment and visual inspection.

One example of an algorithm that is suitable for determining percent sequence identity and sequence similarity is the BLAST algorithm, which is described in Altschul *et al.*, *J. Mol. Biol.* 215:403-410 (1990). Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information (<http://www.ncbi.nlm.nih.gov/>). This algorithm involves first identifying high scoring sequence pairs (HSPs) by identifying short words of length  $W$  in the query sequence, which either match or satisfy some positive-valued threshold score  $T$  when aligned with a word of the same length in a database sequence.  $T$  is referred to as the neighborhood word score threshold (Altschul, *et al.*, *J. Mol. Biol.*, 215:403-410 (1990)). These initial neighborhood word hits act as seeds for initiating searches to find longer HSPs containing them. The word hits are extended in both directions along each sequence for as far as the



cumulative alignment score can be increased. Extension of the word hits in each direction are halted when: the cumulative alignment score falls off by the quantity X from its maximum achieved value; the cumulative score goes to zero or below, due to the accumulation of one or more negative-scoring residue alignments; or the end of either sequence is reached. The BLAST algorithm parameters W, T, and X determine the sensitivity and speed of the alignment. The BLAST program uses as defaults a wordlength (W) of 11, the BLOSUM62 scoring matrix (*see* Henikoff & Henikoff, *Proc. Natl. Acad. Sci. USA* 89:10915 (1989)) alignments (B) of 50, expectation (E) of 10, M=5, N=-4, and a comparison of both strands.

The BLAST algorithm also performs a statistical analysis of the similarity between two sequences (*see, e.g.,* Karlin & Altschul, *Proc. Nat'l. Acad. Sci. USA* 90:5873-5787 (1993)). One measure of similarity provided by the BLAST algorithm is the smallest sum probability (P(N)), which provides an indication of the probability by which a match between two nucleotide or amino acid sequences would occur by chance. For example, a nucleic acid is considered similar to a reference sequence if the smallest sum probability in a comparison of the test nucleic acid to the reference nucleic acid is less than about 0.2, more preferably less than about 0.01, and most preferably less than about 0.001.

Another example of a useful algorithm is PILEUP. PILEUP creates a multiple sequence alignment from a group of related sequences using progressive, pairwise alignments to show relationship and percent sequence identity. It also plots a tree or dendrogram showing the clustering relationships used to create the alignment. PILEUP uses a simplification of the progressive alignment method of Feng & Doolittle, *J. Mol. Evol.* 35:351-360 (1987). The method used is similar to the method described by Higgins & Sharp, *CABIOS* 5:151-153 (1989). The program can align up to 300 sequences, each of a maximum length of 5,000 nucleotides or amino acids. The multiple alignment procedure begins with the pairwise alignment of the two most similar sequences, producing a cluster of two aligned sequences. This cluster is then aligned to the next most related sequence or cluster of aligned sequences. Two clusters of sequences are aligned by a simple extension of the pairwise alignment of two individual sequences. The final alignment is achieved by a series of progressive, pairwise alignments. The program is run by designating specific sequences and their amino acid or nucleotide coordinates for regions of sequence

comparison and by designating the program parameters. For example, a reference sequence can be compared to other test sequences to determine the percent sequence identity relationship using the following parameters: default gap weight (3.00), default gap length weight (0.10), and weighted end gaps.

5 "Conservatively modified variants" applies to both amino acid and nucleic acid sequences. With respect to particular nucleic acid sequences, conservatively modified variants refers to those nucleic acids which encode identical or essentially identical amino acid sequences, or where the nucleic acid does not encode an amino acid sequence, to essentially identical sequences. Because of the degeneracy of the genetic code, a large  
10 number of functionally identical nucleic acids encode any given protein. For instance, the codons GCA, GCC, GCG and GCU all encode the amino acid alanine. Thus, at every position where an alanine is specified by a codon, the codon can be altered to any of the corresponding codons described without altering the encoded polypeptide. Such nucleic acid variations are "silent variations," which are one species of conservatively modified variations. Every nucleic acid sequence herein which encodes a polypeptide also describes  
15 every possible silent variation of the nucleic acid. One of skill will recognize that each codon in a nucleic acid (except AUG, which is ordinarily the only codon for methionine) can be modified to yield a functionally identical molecule. Accordingly, each silent variation of a nucleic acid which encodes a polypeptide is implicit in each described  
20 sequence.

As to amino acid sequences, one of skill will recognize that individual substitutions, deletions or additions to a nucleic acid, peptide, polypeptide, or protein sequence which alters, adds or deletes a single amino acid or a small percentage of amino acids in the encoded sequence is a "conservatively modified variant" where the alteration  
25 results in the substitution of an amino acid with a chemically similar amino acid. Conservative substitution tables providing functionally similar amino acids are well known in the art.

The following six groups each contain amino acids that are conservative substitutions for one another:

- 30 1) Alanine (A), Serine (S), Threonine (T);
- 2) Aspartic acid (D), Glutamic acid (E);
- 3) Asparagine (N), Glutamine (Q);

- 4) Arginine (R), Lysine (K);
- 5) Isoleucine (I), Leucine (L), Methionine (M), Valine (V); and
- 6) Phenylalanine (F), Tyrosine (Y), Tryptophan (W).

(see, e.g., Creighton, *Proteins* (1984)).

5           An indication that two nucleic acid sequences or polypeptides are substantially identical is that the polypeptide encoded by the first nucleic acid is immunologically cross reactive with the antibodies raised against the polypeptide encoded by the second nucleic acid. Thus, a polypeptide is typically substantially identical to a second polypeptide, for example, where the two peptides differ only by conservative substitutions. Another indication that two nucleic acid sequences are substantially identical is that the two molecules or their complements hybridize to each other under stringent conditions, as described below.

10           The phrase "selectively (or specifically) hybridizes to" refers to the binding, duplexing, or hybridizing of a molecule only to a particular nucleotide sequence under stringent hybridization conditions when that sequence is present in a complex mixture (e.g., total cellular or library DNA or RNA).

15           The phrase "stringent hybridization conditions" refers to conditions under which a probe will hybridize to its target subsequence, typically in a complex mixture of nucleic acid, but to no other sequences. Stringent conditions are sequence-dependent and will be different in different circumstances. Longer sequences hybridize specifically at higher temperatures. An extensive guide to the hybridization of nucleic acids is found in Tijssen, *Techniques in Biochemistry and Molecular Biology--Hybridization with Nucleic Probes*, "Overview of principles of hybridization and the strategy of nucleic acid assays" (1993). Generally, highly stringent conditions are selected to be about 5-10 °C lower than  
20 the thermal melting point ( $T_m$ ) for the specific sequence at a defined ionic strength pH. Low stringency conditions are generally selected to be about 15-30 °C below the  $T_m$ . The  $T_m$  is the temperature (under defined ionic strength, pH, and nucleic concentration) at which 50% of the probes complementary to the target hybridize to the target sequence at equilibrium (as the target sequences are present in excess, at  $T_m$ , 50% of the probes are  
25 occupied at equilibrium). Stringent conditions will be those in which the salt concentration is less than about 1.0 M sodium ion, typically about 0.01 to 1.0 M sodium ion concentration (or other salts) at pH 7.0 to 8.3 and the temperature is at least about  
30

30°C for short probes (e.g., 10 to 50 nucleotides) and at least about 60 °C for long probes (e.g., greater than 50 nucleotides). Stringent conditions may also be achieved with the addition of destabilizing agents such as formamide. For selective or specific hybridization, a positive signal is at least two times background, preferably 10 times background hybridization.

Nucleic acids that do not hybridize to each other under stringent conditions are still substantially identical if the polypeptides which they encode are substantially identical. This occurs, for example, when a copy of a nucleic acid is created using the maximum codon degeneracy permitted by the genetic code. In such cases, the nucleic acids typically hybridize under moderately stringent hybridization conditions.

In the present invention, genomic DNA or cDNA comprising nucleic acids useful in the invention can be identified in standard Southern blots under stringent conditions using the nucleic acid sequences disclosed here. For the purposes of this disclosure, suitable stringent conditions for such hybridizations are those which include a hybridization in a buffer of 40% formamide, 1 M NaCl, 1% SDS at 37 °C, and at least one wash in 0.2X SSC at a temperature of at least about 50 °C, usually about 55 °C to about 60 °C, for 20 minutes, or equivalent conditions. A positive hybridization is at least twice background. Those of ordinary skill will readily recognize that alternative hybridization and wash conditions can be utilized to provide conditions of similar stringency.

A further indication that two polynucleotides are substantially identical is if the reference sequence, amplified by a pair of oligonucleotide primers, can then be used as a probe under stringent hybridization conditions to isolate the test sequence from a cDNA or genomic library, or to identify the test sequence in, e.g., a northern or Southern blot.

## BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 is a schematic diagram of recombinant constructs of the invention.

## DETAILED DESCRIPTION OF THE INVENTION

The practice of this invention involves the construction of recombinant nucleic acids and the expression of genes in transfected host cells. Molecular cloning techniques to achieve these ends are known in the art. A wide variety of cloning and *in vitro* amplification methods suitable for the construction of recombinant nucleic acids such

as expression vectors are well-known to persons of skill. Examples of these techniques and instructions sufficient to direct persons of skill through many cloning exercises are found in Sambrook *et al.*, *Molecular Cloning: A Laboratory Manual*, 2nd Ed., Vols. 1-3, Cold Spring Harbor Laboratory (1989); Berger and Kimmel, *Guide to Molecular Cloning Techniques*, *Methods in Enzymology* volume 152 Academic Press, Inc., San Diego, CA; and *Current Protocols in Molecular Biology*, F.M. Ausubel *et al.*, eds., Current Protocols, a joint venture between Greene Publishing Associates, Inc. and John Wiley & Sons, Inc. (1994 Supplement).

#### Preparation of Nucleic Acids of the Invention

Nucleic acids encoding vanadium bromoperoxidase polypeptides of this invention can be prepared by any suitable method known in the art, including, for example, cloning and restriction of appropriate sequences or direct chemical synthesis by methods such as the phosphotriester method of Narang *et al.* (1979) *Meth. Enzymol.* 68: 90-99; the phosphodiester method of Brown *et al.* (1979) *Meth. Enzymol.* 68: 109-151; the diethylphosphoramidite method of Beaucage *et al.* (1981) *Tetra. Lett.*, 22: 1859-1862; and the solid support method of U.S. Patent No. 4,458,066.

In one preferred embodiment, the desired nucleic acids encoding a vanadium bromoperoxidase are isolated by routine cloning methods. A nucleotide sequence encoding the enzyme (as provided below, for example) is used to construct probes that specifically hybridize to a bromoperoxidase gene in a genomic DNA sample, or to mRNA in a total RNA sample (*e.g.*, in a Southern or Northern blot). Once the target nucleic acid is identified, it can be isolated according to standard methods known to those of skill in the art.

The desired nucleic acids can also be cloned using well known amplification techniques. Examples of protocols sufficient to direct persons of skill through *in vitro* amplification methods, including the polymerase chain reaction (PCR) the ligase chain reaction (LCR), Q $\beta$ -replicase amplification and other RNA polymerase mediated techniques are found in Berger, Sambrook, and Ausubel, as well as Mullis *et al.* (1987) U.S. Patent No. 4,683,202; *PCR Protocols A Guide to Methods and Applications* (Innis *et al.* eds) Academic Press Inc. San Diego, CA (1990) (Innis); Arnheim & Levinson (October 1, 1990) *C&EN* 36-47; *The Journal Of NIH Research* (1991) 3: 81-94; (Kwoh *et*

*al.* (1989) *Proc. Natl. Acad. Sci. USA* 86: 1173; Guatelli *et al.* (1990) *Proc. Natl. Acad. Sci. USA* 87: 1874; Lomell *et al.* (1989) *J. Clin. Chem.* 35: 1826; Landegren *et al.* (1988) *Science* 241: 1077-1080; Van Brunt (1990) *Biotechnology* 8: 291-294; Wu and Wallace (1989) *Gene* 4: 560; and Barringer *et al.* (1990) *Gene* 89: 117. Improved methods of cloning *in vitro* amplified nucleic acids are described in Wallace *et al.*, U.S. Pat. No. 5,426,039. Suitable primers for use in the amplification of the nucleic acids of the invention are described in the Example Section, below.

The desired nucleic acid can also be cloned by detecting its expressed product by means of assays based on the physical, chemical, or immunological properties of the expressed protein. For example, one can identify a cloned bromoperoxidase nucleic acid by the ability of a polypeptide encoded by the nucleic acid to catalyze the oxidation of o-dianisidine HCl (ODA) as described in the examples below.

In some embodiments, it may be desirable to modify the bromoperoxidase nucleic acids of the invention. One of skill will recognize many ways of generating alterations in a given nucleic acid construct. Such well-known methods include site-directed mutagenesis, PCR amplification using degenerate oligonucleotides, exposure of cells containing the nucleic acid to mutagenic agents or radiation, chemical synthesis of a desired oligonucleotide (*e.g.*, in conjunction with ligation and/or cloning to generate large nucleic acids) and other well-known techniques. *See, e.g.*, Gilman and Smith (1979) *Gene* 8:81-97, Roberts *et al.* (1987) *Nature* 328: 731-734. The modified polypeptides can be tested for activity using the ODA assays described below.

#### Preparation of Expression Cassettes Encoding Bromoperoxidase Polypeptides of the Invention

The nucleic acid sequences of the invention are incorporated into expression cassettes for high level expression in a desired host cell according to techniques well known to those of skill in the art. The particular host cell used is not critical to the invention and can be either a prokaryotic or eukaryotic cell, as described below.

A typical expression cassette contains a promoter operably linked to the desired DNA sequence. Commonly used prokaryotic control sequences, which are defined herein to include promoters for transcription initiation, optionally with an operator, along with ribosome binding site sequences, include such commonly used promoters as the beta-

lactamase (penicillinase) and lactose (*lac*) promoter systems (Change *et al.*, *Nature* (1977) 198: 1056), the tryptophan (*trp*) promoter system (Goeddel *et al.*, *Nucleic Acids Res.* (1980) 8: 4057), the tac promoter (DeBoer, *et al.*, *Proc. Natl. Acad. Sci. U.S.A.* (1983) 80:21-25); and the lambda-derived P<sub>L</sub> promoter and N-gene ribosome binding site (Shimatake *et al.*, *Nature* (1981) 292: 128). The particular promoter system is not critical to the invention, any available promoter that functions in prokaryotes can be used.

Either constitutive or regulated promoters can be used in the present invention. Regulated promoters can be advantageous because the host cells can be grown to high densities before expression of the bromoperoxidase polypeptides is induced. High level expression of heterologous proteins slows cell growth in some situations. Regulated promoters especially suitable for use in *E. coli* include the bacteriophage lambda P<sub>L</sub> promoter, the hybrid *trp-lac* promoter (Amann *et al.*, *Gene* (1983) 25: 167; de Boer *et al.*, *Proc. Natl. Acad. Sci. USA* (1983) 80: 21, and the bacteriophage T7 promoter (Studier *et al.*, *J. Mol. Biol.* (1986); Tabor *et al.*, (1985). These promoters and their use are discussed in Sambrook *et al.*, *supra*.

For expression of the polypeptides in prokaryotic cells other than *E. coli*, a promoter that functions in the particular prokaryotic species is required. Such promoters can be obtained from genes that have been cloned from the species, or heterologous promoters can be used. For example, the hybrid *trp-lac* promoter functions in *Bacillus* in addition to *E. coli*.

A ribosome binding site (RBS) is conveniently included in the expression cassettes of the invention. An RBS in *E. coli*, for example, consists of a nucleotide sequence 3-9 nucleotides in length located 3-11 nucleotides upstream of the initiation codon (Shine and Dalgarno, *Nature* (1975) 254: 34; Steitz, *In Biological regulation and development: Gene expression* (ed. R.F. Goldberger), vol. 1, p. 349, 1979, Plenum Publishing, NY).

Translational coupling may be used to enhance expression. The strategy uses a short upstream open reading frame derived from a highly expressed gene native to the translational system, which is placed downstream of the promoter, and a ribosome binding site followed after a few amino acid codons by a termination codon. Just prior to the termination codon is a second ribosome binding site, and following the termination codon is a start codon for the initiation of translation. The system dissolves secondary

structure in the RNA, allowing for the efficient initiation of translation. See Squires, et. al. (1988), *J. Biol. Chem.* 263: 16297-16302.

The polypeptides can be expressed intracellularly, or can be secreted from the cell. Intracellular expression often results in high yields. If necessary, the amount of soluble, active polypeptide may be increased by performing refolding procedures (*see, e.g.,* Sambrook *et al., supra.*; Marston *et al., Bio/Technology* (1984) 2: 800; Schoner *et al., Bio/Technology* (1985) 3: 151).

In embodiments in which the bromoperoxidase polypeptides are secreted from the cell, either into the periplasm or into the extracellular medium, the DNA sequence is linked to a cleavable signal peptide sequence. The signal sequence directs translocation of the bromoperoxidase polypeptide through the cell membrane. An example of a suitable vector for use in *E. coli* that contains a promoter-signal sequence unit is pTA1529, which has the *E. coli phoA* promoter and signal sequence (*see, e.g.,* Sambrook *et al., supra.*; Oka *et al., Proc. Natl. Acad. Sci. USA* 82: 7212 (1985); Talmadge *et al., Proc. Natl. Acad. Sci. USA*, 77:3988 (1980); Takahara *et al., J. Biol. Chem.*, 260:2670 (1985)).

One of skill would recognize that other modifications can be made to the bromoperoxidase polypeptides without diminishing their biological activity. Some modifications may be made to facilitate the cloning, expression, and the like. Such modifications are well known to those of skill in the art and include, for example, a methionine added at the amino terminus to provide an initiation site, or additional amino acids that form an epitope tag (*e.g.,* poly His) placed on either terminus to facilitate purification. In addition, one of skill will recognize that fusion proteins with various heterologous protein sequences can be prepared. For example, overexpression of a protein can lead to the accumulation of folding intermediates which have a tendency to aggregate. Production of fusion proteins including sequences, such as bacterial thioredoxin, can be used to facilitate proper folding. The polypeptides of the invention can also be linked to other bacterial proteins. This approach often results in high yields, because normal prokaryotic control sequences direct transcription and translation. In *E. coli*, *lacZ* fusions are often used to express heterologous proteins. Suitable vectors are readily available, such as the pUR, pEX, and pMR100 series (*see, e.g.,* Sambrook *et al., supra.*).



For certain applications, it may be desirable to cleave the non-bromoperoxidase amino acids from the fusion protein after purification. This can be accomplished by any of several methods known in the art, including cleavage by cyanogen bromide, a protease (e.g., enterokinase), or by Factor X<sub>a</sub>, (see, e.g., Sambrook *et al.*, *supra.*; Itakura *et al.*, *Science* (1977) 198: 1056; Goeddel *et al.*, *Proc. Natl. Acad. Sci. USA* (1979) 76: 106; Nagai *et al.*, *Nature* (1984) 309: 810; Sung *et al.*, *Proc. Natl. Acad. Sci. USA* (1986) 83: 561). Cleavage sites can be engineered into the gene for the fusion protein at the desired point of cleavage.

A suitable system for obtaining recombinant proteins from *E. coli* which maintains the integrity of their N-termini has been described by Miller *et al.* *Biotechnology* 7:698-704 (1989). In this system, the gene of interest is produced as a C-terminal fusion to the first 76 residues of the yeast ubiquitin gene containing a peptidase cleavage site. Cleavage at the junction of the two moieties results in production of a protein having an intact authentic N-terminal residue.

#### Expression of Bromoperoxidase Polypeptides of the Invention

Bromoperoxidases of the invention can be expressed in a variety of host cells, including *E. coli*, other bacterial hosts, yeast, and various higher eukaryotic cells such as algal cells. For example microalgal expression systems, useful in the invention include the diatom *Phaeodactylum tricornutum* (Apt *et al.* *J. Phycol.* 32:4 (1996)).

Examples of useful bacteria include, but are not limited to, *Escherichia*, *Enterobacter*, *Azotobacter*, *Erwinia*, *Bacillus*, *Pseudomonas*, *Klebsiella*, *Proteus*, *Salmonella*, *Serratia*, *Shigella*, *Rhizobia*, *Vitreoscilla*, and *Paracoccus*. The recombinant protein gene will be operably linked to appropriate expression control sequences for each host. For *E. coli* this includes a promoter such as the T7, trp, or lambda promoters, a ribosome binding site and preferably a transcription termination signal. For eukaryotic cells, the control sequences will include a promoter and preferably an enhancer derived from immunoglobulin genes, SV40, cytomegalovirus, *etc.*, and a polyadenylation sequence, and may include splice donor and acceptor sequences.

The expression vectors of the invention can be transferred into the chosen host cell by well-known methods such as calcium chloride transformation for *E. coli* and calcium phosphate treatment or electroporation for mammalian cells. Cells transformed by

the plasmids can be selected by resistance to antibiotics conferred by genes contained on the plasmids, such as the *amp*, *gpt*, *neo* and *hyg* genes.

Once expressed, the recombinant bromoperoxidase polypeptides can be purified according to standard procedures of the art, including ammonium sulfate precipitation, affinity columns, column chromatography, gel electrophoresis and the like (see, generally, R. Scopes, *Protein Purification*, Springer-Verlag, N.Y. (1982), Deutscher, *Methods in Enzymology Vol. 182: Guide to Protein Purification.*, Academic Press, Inc. N.Y. (1990)). Substantially pure compositions of at least about 90 to 95% homogeneity are preferred, and 98 to 99% or more homogeneity are most preferred. Once purified, partially or to homogeneity as desired, the polypeptides may then be used (e.g., as immunogens for antibody production).

The purified bromoperoxidase polypeptides of the invention can be used in a number of industrial applications. The polypeptides can be used for any purpose to which prior art haloperoxidases are used. For instance, the polypeptides can be used to halogenate various substrates, including proteins. For instance the polypeptides can be used to produce epoxides from alkenes, halogenated ketones from alkynes, to produce alpha, gamma-halohydrins from cyclopropanes, and to produce dihalogenated products from alkenes and alkynes. In addition, the ability of the polypeptides to oxidize various compounds make them useful, for instance, in signal generating systems in place of horseradish peroxidase. Thus, the bromoperoxidase polypeptides of the invention can be used as a component in assays as described in WO 97/09619. The polypeptides can also be as enzymatic antimicrobial agents (see, e.g., WO 95/27046). Other uses include production of phenolic adhesives as described in U.S. Patent No. 5,520,727.

#### Example 1

This example describes the cloning of a vanadium bromoperoxidase gene of the invention.

#### MATERIALS AND METHODS

DNA library. A *Fucus distichus* 2-cell embryos c-DNA library was prepared the  $\lambda$ -ZipLoxL1 plasmid (Gibco BRL, Gaithersburg, MD) and is described in Goodner, et al., *Plant Physiology*, 107:1007-1008 (1995).

Antibody screening. An antibody to *Corallina vancouverensis* vanadium peroxidase was prepared which identified *Fucus distichus* vanadium peroxidase on Western blots of crude extracts.

DNA Hybridization Method. Hybridization probes were prepared at the second and near the third regions shown to be conserved between *Curvularia* and *Ascophyllum* vanadium peroxidase active sites by Messerschmidt, *et al.*, *PNAS*, 93:392-396 (1996). Hybridization probes of 51 base pairs were designed with Oligo 5.0 Primer Analysis Software (National Biochemicals, Plymouth, MN), synthesized by Anagen (Palo Alto), and digoxigenin-labeled at the 5' end with the Genius system (BMB Biochemicals, Durham, NC). The sequence of the probe for the second conserved site was: CCAACGCACCCTTCGTACCCGTCTGGCCACGCTACCCAAAACGGAGCATTT. The sequence of the probe for the third conserved site was: CCGTACGAACACTTCACCAGGAGCTGATGACTTTCGCCGAGGAATCCACCT.

Sequencing. Sequencing of the *Fucus* vanadium peroxidase clone was accomplished by primer walking. M13 universal primers and primers designed from *Fucus* and *Ascophyllum* Vanadium haloperoxidase sequences with Oligo software and synthesized by Operon (Alameda, CA). ABI dye-terminator sequencing was done by the UCB Molecular and Cellular Biology DNA Sequencing Facility in Barker Hall.

Homology. DNA and protein searches on databases accessible online through GenBank using the BLAST algorithm (Altshul, *et al.*, *J. Mol. Biol.*, 215:403-410 (1990)).

Protein Expression In order to optimize correct folding for peroxidase activity, recombinant *Fucus* vanadium peroxidase constructs were prepared and expressed in *E. coli* as fusion proteins with thioredoxin at the N-terminal end (pET-32 LIC Ligation Independent Cloning vector, Novagen, Madison, WI). This vector produces a high level of expression of soluble recombinant proteins in *E. coli* cytoplasm. The expressed protein is fused with an N-terminal thioredoxin (Trx-Tag™), S-Tag™ and His-Tag™ for optimizing correct protein folding, detection and purification, respectively (Novagen). In addition, an enterokinase (EK) cleavage site is located at the N-terminal end of the inserted protein so that native protein can be cleaved from the 19 kDa tagged peptide following expression. Three sizes of constructs were prepared for confirmation of the active site domain at the 3' end, as suggested by the minimal fungal-*Ascophyllum* homology reported at the active site

(Messerschmidt, *et al.*, *PNAS*, 93:392-396 (1996)). Expression constructs were prepared for the full length *Fucus* bromoperoxidase and two 5'-truncated forms (Table 1), corresponding to 100%, 80% and 54% of the full length sequence, respectively. The cloned  $\lambda$ -ZipLox plasmid containing the *Fucus* vanadium bromoperoxidase cDNA was used as the template for PCR amplification with Vent DNA polymerase (New England Biolabs, Beverly, MA).

Table 1

Construct Designation	Starting point (bp #) on SEQ ID NO:1	VPx bp expressed	kD of Vpx sequence	Expressed fusion protein size in kD
rVPx1	1	2028	73.5	93
rVPx2	409	1620	57.7	77
rVPx3	937	1092	39.6	59

The following *Fucus* peroxidase LIC primers were designed with Oligo software (National Biosciences, Inc., Plymouth, MN) and pET-32 LIC sequences necessary for incorporated into the vector (normal font). Primers for the 5' end were: GACGACGACAAGATGCTTTGCCATGCAGCGGACA (34 bp) for the full length construct, GACGACGACAAGATGGCGCCGAATAGAAGGGACAA (35 bp) for the mid length construct, and GACGACGACAAGATGCTCTTCCGAGCGACCTTC (33 bp) for the short construct. One 3'-primer, GAGGAGAAGCCCGTTGCACTAAGCCTGGCAGT (33 bp) was used for all three constructs. PCR was carried out for 30 cycles of 3 min at 94 °, 1.5 min at 55 ° C and 2.3 min at 72 ° C, in 7 mM MgSO<sub>4</sub> for the full length construct and 4 mM MgSO<sub>4</sub> for the two truncated constructs. The PCR products were electrophoresed in 1.5% agarose and stained with ethidium bromide. DNA was extracted from the excised bands in GenElute minus EtBr spincolumns (Supelco, Bellefonte, PA) and precipitated with ethanol.

Ligation independent cloning was carried out according to the pET-32 LIC protocol (Novagen), with a T4 DNA ligase (GibcoBRL, Grand Island, NY) step added prior to transformation for the full length construct. The recombinant plasmids were transformed into the NovaBlue strain of *E. coli* according to the Novagen protocol. In all

bacterial strains transformed, plasmid clones containing peroxidase inserts were identified by PCR of partial Fucus peroxidase sequences with Taq polymerase (Promega, Madison, WI) in 1.6 - 3.75 mM MgCl<sub>2</sub> for 30 cycles of 3 min at 94 °, 1.5 min at 45 ° and 2 min at 72 °, followed by agarose electrophoresis. Plasmids cloned from NovaBlue cells were expressed in BL21(DE3), BL21(DE3) pLysS and AD494(DE3) E. coli cells (Novagen). The AD494 strain is deficient in thioredoxin reductase, which results in an appropriate redox potential for correct folding of eukaryotic proteins (Novagen). Induced bacterial cytoplasmic protein preparations were examined by protein electrophoresis, and the products were tested for vanadium-dependent peroxidase activity. Proteins were expressed for 0, 0.5, 1.5 and 3 h after induction of protein synthesis with IPTG (isopropylthio- $\beta$ -galactoside). Bacterial lysates were prepared immediately after protein expression.

The recombinant bromoperoxidase proteins were immediately purified from bacterial cytoplasmic proteins by affinity chromatography. The HisTag (a sequence of 6 histidines, 6xHis) in the fusion protein was bound to a nickel nitriloacetic acid (Ni+2-NTA) agarose column (Sigma, St. Louis, MO) according to the standard Qiagen protocol. The bound recombinant protein containing 6xHis was eluted with 1M imidazole in 20 mM Tris-HCl pH 7.9 and 500 mM NaCl. Denatured protein samples were electrophoresed in 8% polyacrylamide gels containing 4% SDS, fixed and stained with Coomassie Brilliant Blue R250. The recombinant vanadium peroxidases (rVPx) were tested for vanadium-dependent peroxidase activity on dot blots. A preliminary in vitro expression experiment was carried out for the three LIC constructs in a bacteriophage transcription system linked with a rabbit reticulocyte translation system (Single Tube Protein System 2, T7, Novagen), and the products were tested for vanadium-dependent peroxidase activity on dot blots.

Vanadium peroxidase activity assay. Peroxidase activity with ODA (o-dianisidine HCl, Sigma) as the substrate was detected by dot blotting 1  $\mu$ L of enzyme solution onto positively charged nylon membranes (Biodyne B, Pall Corp., Port Washington, NY). Substrate solution contained 100 mM Tris-HCl, pH 8.0, 10 mM KBr, 0.25 mM urea-H<sub>2</sub>O<sub>2</sub>, and 1 mM ODA (Sigma). Quantities of dry KBr, urea-H<sub>2</sub>O<sub>2</sub> and ODA were estimated for daily substrate solutions.

RVPx were rapidly revanadated with trace levels of vanadium. 1  $\mu$ L of 100 mM sodium orthovanadate in a 2  $\mu$ L pipettor tip was ejected from the tip. The "vanadated" empty tip was then inserted into a 5-10  $\mu$ L drop of enzyme solution on a piece of Parafilm (Fisher, Hayward, CA) and pipetted in and out 5 times. After waiting 1-5 min, 1  $\mu$ L of the revanadated rVPx was pipetted onto the nylon membrane and air dried for a few minutes. While strong peroxidase activity was visible in a few minutes, the membrane was incubated in the ODA solution overnight.

Antibody labeling on Membranes (Plaque Lifts, Dot Blots and Western Blots). The membranes were blocked overnight at 4° C in 100 mM Tris-HCl pH 8.0 + 4% skim milk + 0.1% tween-20 and then incubated for 3 h at 37° C in mouse ascites antibody to *Corallina* vanadium peroxidase or mouse ascites control antibody (Sigma) diluted 1:1,000 in blocking solution. The blots were washed 3X in blocking solution and incubated in alkaline phosphatase-conjugated anti-mouse second antibody (diluted 1:5,000) for 1 h at room temperature. They were then washed 3X in blocking solution and rinsed in alkaline buffer (100 mM NaCl + 100 mM Tris-HCl at pH 9.5. + 50 mM MgCl<sub>2</sub>). Chemiluminescence was detected by of CPD-Star (BMB, Durham, NC) (diluted 1: in alkaline buffer) and exposed to X-ray film (Kodak) for 2 h. Alternative colorigenic detection was by overnight incubation in NBT/BCIP substrate (Pierce, Rockford, IL).

## RESULTS

Fucus cDNA library Screening. The fusion protein for the VPx clone which was expressed during cDNA screening was apparently truncated prior to the VPx start codon, at a TGA stop codon located at bases 82-84 in the 5' UTR. This truncation upstream of the VPx coding sequence caused a lack of VPx protein expression during screening, explaining the lack of a-VPx antibody labeling during extensive screening. Therefore, two 51 bp DNA probes based on two small regions of homology at the active site between *Curvularia* chloroperoxidase and *Ascophyllum* bromoperoxidase (Messerschmidt, *et al.*, *PNAS*, 93:392-396 (1996)) were used to screen the *Fucus* embryo cDNA library. Only one clone was identified which was labeled with both of the VPx DNA probes after extensive screening. This clone was about 3 kb in size after Not I/Sal I excision from the plasmid.

Fucus vanadium peroxidase sequence. The sequence of the VPX from 2-cell *Fucus gardneri* embryos is shown in SEQ ID NO:1. The 2931 base pairs in the

Fucus cDNA clone includes 227 bases in the 5' UTR, 2031 bases in the coding region and 673 bases in the 3' UTR. The 5' UTR is a partial sequence, and the 3' UTR is complete. Translation of the VPx coding sequence produces a 73,353 Da protein containing 676 amino acids. No obvious leader peptide sequence was detected although VPx is secreted (Vreeland, *et al.*, *Molecular Biology of the Cell* 7 (Supplement), 304a (1996)).

A 73.4 kDa Fucus monomer would be the largest known VPx monomer, although the molecular mass of the native *Fucus* enzyme is unknown. The 73.4 kDa size is larger than the 60 kDa VPx monomer from a related brown alga, *Ascophyllum nodosum*, as well as larger than the 67.5 kDa fungal *Curvularia inaequalis* chloroperoxidase monomer (Simons, *et al.*, *European Journal of Biochemistry*, 229:566-574 (1995)). The *Fucus* VPx monomer comigrated with the monomer of the red alga *Corallina vancouverensis* on PAGE gels (Vreeland, *et al.*, *Molecular Biology of the Cell* 7 (Supplement), 304a (1996)). The *C. officinalis* and *C. pilulifera* VPx monomers are approximately 64 kDa based on SDS PAGE data (Itoh, *et al.*, *J. Biological Chemistry* 261:5194-5200 (1986); Sheffield, *et al.*, *Phytochemistry*, 32:21-26 (1993); Rush, *et al.*, *FEBS Letters*, 359:244-246 (1995)), and the *Fucus* VPx monomer might therefore be expected to be a similar size. However, the related *Fucus* and *Ascophyllum* brown algal VPx monomer sizes differ, and it is also possible that the *C. vancouverensis* monomer size may differ from the published *C. officinalis* and *C. pilulifera* monomer size.

Alternative explanations include utilization of the third start codon in the *Fucus* VPx sequence to produce a 64,471 Da protein of 596 amino acids. Utilization of the third start codon is supported by the lack of a TATA box upstream of the first two start codons, and the presence of a TATA box 79 bp upstream of the third in-frame ATG. Also possible are different protein shape and/or charge properties resulting in electrophoretic comigration of *Fucus* and *C. vancouverensis* monomers.

The *Fucus* and *C. vancouverensis* multimers also comigrated, implying that the *Fucus* multimer may be a dodecamer (Vreeland, *et al.*, *Molecular Biology of the Cell* 7 (Supplement), 304a (1996)) although the *Ascophyllum* multimer is a dimer (Vilter 1995), since the *C. officinalis* and *C. pilulifera* multimers appear to be dodecamers (Sheffield, *et al.*, *Phytochemistry*, 32:21-26 (1993); Rush, *et al.*, *FEBS Letters*, 359:244-246 (1995); Itoh, *et al.*, *J. Biological Chemistry* 261:5194-5200 (1986)). Although the C-terminal catalytic domain appears to be similar in *Fucus* and *Ascophyllum* VPx, their

self-associating domains are likely to differ due to their different monomer sizes. The *Fucus* VPx may contain more than one self-associating domain if it contains the double hexameric ring arrangement as found for the *C. pilulifera* VPx by Itoh, *et al.*, *J. Biological Chemistry* 261:5194-5200 (1986), and this may partially account for the larger size of the *Fucus* VPx in the N-terminal region.

The *Fucus* and *Ascophyllum* brown algal VPx were 87.2% identical for 709 base pairs of DNA and 85.8% identical for 232 amino acids for the published partial C-terminal VPx sequence of *Ascophyllum* (Vilter 1995) when calculated from the best match of the *Fucus* data with the published *Ascophyllum* peptide and translated sequences.

The *Fucus* sequence contains three conserved vanadium-binding regions (Messerschmidt *et al.*). The three conserved vanadium-binding regions are as follows: (1) amino acids 452-473 AQRASCYQKWQVHRFARPEALG; (2) amino acids 528-546 PTHPSYPSGHATQNGAFAT and (3) amino acids 591-609 LAVNVAFGRQMLGIHYRFD. In the three conserved vanadium-binding regions the *Fucus* and *Ascophyllum* amino acid sequences differ only at two locations in the first conserved region (alanine at F455 substituted for serine at A19, and cysteine at F 457 substituted for tryptophan at A21). These two amino acid differences are therefore likely to be related to the greater specific activity of the *Fucus* enzyme, as are other amino acid sequence differences in the catalytic domain (amino acids F441-676). A major difference between the *Fucus*, *Ascophyllum* and *Corallina* algal bromoperoxidases and the fungal chloroperoxidases and various phosphatases is the additional basic amino acids in the first conserved domain of the bromoperoxidases, histidine at F464 and leucine at F472 for the brown algal enzymes, with threonine instead of leucine for the *Corallina* enzyme. These additional amino acids in the first conserved region are likely to be related to the greater activity of the bromoperoxidases with bromide, which is larger than the chloride ion.

Bacterial expression of *Fucus* vanadium peroxidase constructs. The three recombinant *Fucus* VPx proteins (rVPx, Table 1, Figure 1) were expressed as soluble cytoplasmic proteins in both BL21(DES) and AD494 strains of *E. coli* at the expected sizes of recombinant proteins. All of the recombinant proteins were seen as major bands against the background of bacterial proteins. This represents production of about 1-10 mg/100 mL of recombinant proteins, as estimated from the intensity of Coomassie blue-stained bands.



After Ni-NTA column purification, peroxidase activity for rVPx expressed by AD494 cells was tested on dot blots with 0-dianisidine as substrate. No peroxidase activity was detected in the absence of added vanadium, although *E. coli* contains an 80 kDa 0-dianisidine-reactive peroxidase. This result with an extremely sensitive activity assay also demonstrates that the single affinity purification step removed significant contamination by bacterial proteins.

Peroxidase activity was detected in all three rVPx constructs immediately following protein expression and purification, but only in the presence of added vanadium. The activity was relatively weak, and decreased with smaller rVPx construct size. However, after overnight treatment at -20° C, activity was much stronger and of similar intensity for all three construct sizes. Like native algal VPx, the recombinant forms bound to positively charged nylon membranes but did not bind to nitrocellulose membranes. However, the recombinant forms did not bind as tightly to nylon membranes.

The three sizes of rVPx were also expressed in an *in vitro* rabbit reticulocyte system. It was clear that expression of all three sizes of rVPx occurred, although background peroxidase activity was seen in this eukaryotic system.

## DISCUSSION

ODA is a common substrate for heme peroxidases such as horseradish peroxidase and other peroxidases. The product of ODA oxidation by algal vanadium peroxidase was not halogenated, although it is not known whether ODA oxidation by rVPx involves a halogenated intermediate or singlet O<sub>2</sub> production. The expression of active rVPx in *E. coli* demonstrates that glycosylation is not necessary for enzyme activity, and, indeed, the native enzyme is probably not glycosylated. Activity of recombinant enzyme shows that it can be folded correctly in bacterial cytoplasm, as well.

The above examples are provided to illustrate the invention but not to limit its scope. Other variants of the invention will be readily apparent to one of ordinary skill in the art and are encompassed by the appended claims. All publications, GenBank Accession references (sequences), patents and patent applications cited herein are hereby expressly incorporated by reference for all purposes.